Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: A systematic review and meta-analysis

Behzad Haghighi Askia, Ali Manafi Anari, Farhad Abolhasan Choobdar, Ramin Zareh Mahmoudabadi, Maryam Sakhaei

Department of Pediatrics, Ali Asghar Children’s Hospital, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Cardiac defects due to multisystem inflammatory syndrome in children (MIS-C) have been abundantly reported leading high morbidity among children affected by Covid-19. We aimed to systematically assess the incidence of such cardiac abnormalities due to MIS-C in children suffering Covid-19.

Methods: The manuscript databases including Medline, Web of knowledge, Google scholar, Scopus, and Cochrane were deeply searched by the two blinded investigators for all eligible studies based on the relevant keywords. The risk of bias for each study was assessed according to QUADAS-2 tool. Statistical analysis was performed using the Comprehensive Meta Analysis (CMA) software.

Results: In final, 21 articles (including 916 children) were eligible for the final analysis that all yielded good quality and none of the citation was determined to have high risk of bias. Considering studies focusing different cardiac abnormalities related to MIS-C yielded a pooled prevalence of 38.0% for significant left ventricular dysfunction, 20.0% for coronary aneurism or dilatation, 28.1% for ECG abnormalities or cardiac arrhythmias, 33.3% for raised serum troponin level and 43.6% for raised proBNP/BNP level.

Conclusion: Although cardiac abnormalities among children suffering Covid-19 are uncommon, in the context of the MIS-C can be common and therefore potentially serious and life threatening.

© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Until the current writing, more than 68 million cases of Covid-19 have been reported worldwide, leading to more than 1.5 million deaths [1]. Apart from the pulmonary effects and disabilities associated with the progression of the infection, cardiovascular disorders have been reported in patients suffering this disorder [2]. Coronary atherosclerosis leading to myocardial infarction, myocarditis, valvular defects, peripheral vascular complications due to increased coagulation, and even acute heart failure due to severe left ventricular dysfunction have all been reported complications of the disease [3–5]. The probable mechanisms related to cardiac injuries include both direct invasion of virus leading cardiomyocyte death or indirect myocardial injury due to activation of inflammatory or coagulative cascades, hypoxemia, or metabolic disturbances [6].

Less information is available about children with the disease and its potential complications in childhood, and according to some claims, children are at a much lower risk of contracting

![Flowchart of screening the eligible studies](image)

Fig. 1. The flowchart of screening the eligible studies.

| Author                  | Country  | Number | Mean age | Male/Female | RT-PCR (+) |
|-------------------------|----------|--------|----------|-------------|------------|
| Belhadjer et al (13)    | Switzerland | 35     | 10       | 18/17       | 14/35      |
| Blondiaux et al (14)    | France   | 4      | 9        | 1/3         | 0/4        |
| Cheung et al (15)       | USA      | 17     | 8        | 8/9         | 8/17       |
| Chiotos et al (16)      | USA      | 6      | 14       | 1/5         | 3/6        |
| Dufort et al (17)       | USA      | 99     | 12       | 53/46       | 50/94      |
| Feldstein et al (18)    | USA      | 186    | 8        | 115/71      | 73/186     |
| Gaitonde et al (19)     | USA      | 12     | 8        | 9/3         | 4/12       |
| Grimaud et al (20)      | France   | 20     | 10       | 10/10       | 10/20      |
| Kaushik et al (21)      | USA      | 33     | 10       | 20/13       | 11/33      |
| Matsuabara et al (22)   | USA      | 28     | 11       | 14/14       | 14/28      |
| Minocha et al (23)      | USA      | 33     | 3        | 19/14       | 11/33      |
| Pouletty et al (24)     | France   | 16     | 10       | 8/8         | 11/16      |
| Ramcharan et al (25)    | UK       | 15     | 9        | 11/4        | 2/15       |
| Riphagen et al (26)     | UK       | 8      | 12       | 5/3         | 2/8        |
| Theocharis et al (27)   | UK       | 20     | 10       | 15/5        | 2/20       |
| Toubiana et al (28)     | France   | 21     | 8        | 9/12        | 8/21       |
| Valverde et al (29)     | UK       | 286    | 8        | 194/92      | 96/286     |
| Verdini et al (30)      | Italy    | 10     | 7        | 7/3         | 2/10       |
| Waltruch et al (31)     | USA      | 4      | 9        | 3/1         | 0/3        |
| Whittaker et al (32)    | UK       | 58     | 9        | 25/33       | 15/58      |
| Wolff et al (33)        | Italy    | 5      | 7        | 2/3         | 5/5        |
and dying from the disease [7]. Also, cardiac abnormalities among children suffering Covid-19 is infrequent finding, however it can be life-threatening and also with permanent heart defects [8]. Although the incidence of cardiac abnormalities related to Covid-19 are uncommon among children (with an overall incidence of 0.6%) [9], the occurrence of such abnormalities in the background of critical situation such as multisystem inflammatory syndrome in children (MIS-C) has been frequently reported [10]. According to the definition released by the World Health Organization (WHO), MIS-C is characterized in Children and adolescents (aged 0 to 19 years) by appearing fever (more than three days) with at least two of the following findings: 1) rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs, 2) hypotension or shock, 3) any evidences of cardiac dysfunction along with raising Troponin and NT-proBNP levels, 4) any evidence of coagulopathy, 5) acute gastrointestinal problems, 6) increasing inflammatory markers such as ESR and CRP, all in the background of Covid-19 disease [11]. As reported in the last months, cardiac defects due to MIS-C have been abundantly reported leading high morbidity among children affected by Covid-19 [12]. However, so far no consensus has been reached on such cardiac complications. We aimed to systematically assess the incidence of such cardiac abnormalities due to MIS-C in children suffering Covid-19 that in this way, it is possible to identify the various dimensions of such cardiac defects and improve the survival of the affected children.

2. Materials and methods

2.1. Study selection

The present systematic review and meta-analysis followed the guideline for the Preferred Reporting Items for Systematic review

| Patient selection | Index test | Outcomes | Flow and timing |
|-------------------|------------|----------|-----------------|
| Chiotos et al     | +          | +        | +               |
| Waltuch et al     | +          | +        | ?               |
| Wolfler et al     | +          | +        | +               |
| Grimaud et al     | +          | ?        | +               |
| Toubiana et al    | +          | +        | ?               |
| Whittaker et al   | +          | +        | ?               |
| Blondiaux et al   | +          | +        | +               |
| Cheung et al      | +          | ?        | +               |
| Ramcharan et al   | +          | +        | +               |
| Pouletty et al    | +          | +        | +               |
| Kaushik et al     | +          | ?        | +               |
| Dufort et al      | +          | +        | +               |
| Feldstein et al   | ?          | +        | +               |
| Riphagen et al    | +          | +        | +               |
| Verdoni et al     | +          | +        | +               |
| Belhadjer et al   | +          | +        | +               |
| Matsubara et al   | ?          | +        | +               |
| Theocaris et al   | +          | +        | +               |
| Gaitonde et al    | +          | ?        | +               |
| Valverde et al    | +          | +        | +               |
| Minocha et al     | +          | +        | ?               |

Fig. 2. Assessment of the risk of bias.
and Meta-Analysis (PRISMA). Firstly, the main study questions was suggested based on the authors purposes as “What is the prevalence of each of the cardiac abnormalities caused by MIS-C in the relation to Covid-19 among children?” In the next step, the manuscript databases including Medline, Web of knowledge, Google scholar, Scopus, and Cochrane were deeply searched by the two blinded investigators for all eligible studies based on the considered keywords including “children”, “Covid-19”, “multisystem inflammatory syndrome”, “heart”, and “cardiovascular”. The inclusion criteria were considered to retrieve the studies: 1) the studies

Table 2
Cardiac manifestations in study population.

| Author           | Number | LV dysfunction (LVEF < 35) | Coronary aneurism/dilation | Abnormal ECG | Raised troponin | Raised proBNP/BNP |
|------------------|--------|---------------------------|---------------------------|--------------|-----------------|------------------|
| Chiotos et al    | 6      | 4                         | 1                         | –            | 3               | 3                |
| Waltuch et al    | 4      | 4                         | 3                         | –            | 3               | 3                |
| Wolff et al      | 5      | 3                         | –                         | 1            | –               | –                |
| Grimaud et al    | 20     | 20                        | –                         | 5            | 2               | 17               |
| Toubiana et al   | 21     | 16                        | 5                         | 2            | 6               | –                |
| Whittaker et al  | 58     | 18                        | 8                         | 6            | –               | 29               |
| Blondiaux et al  | 4      | 1                         | –                         | 2            | 4               | 4                |
| Cheung et al     | 17     | 6                         | 7                         | 4            | 14              | 15               |
| Ramcharan et al  | 15     | 12                        | 14                        | 9            | 15              | 15               |
| Verdini et al    | 16     | 7                         | 3                         | –            | 11              | 11               |
| Kaushik et al    | 33     | 4                         | 6                         | –            | –               | –                |
| Dufort et al     | 99     | 51                        | 9                         | –            | 63              | 74               |
| Feldstein et al  | 186    | 90                        | 15                        | 12           | 50              | 73               |
| Riphagen et al   | 8      | 6                         | 1                         | 1            | 1               | 8                |
| Verdini et al    | 10     | 5                         | 2                         | –            | 5               | 10               |
| Belhadjer et al  | 35     | 10                        | –                         | 2            | 1               | 35               |
| Matsubara et al  | 28     | 11                        | 4                         | –            | –               | –                |
| Theocharis et al | 20     | 8                         | 3                         | –            | –               | –                |
| Gaitonde et al   | 12     | 8                         | –                         | –            | –               | –                |
| Valverde et al   | 286    | 59                        | 76                        | 101          | 20              | 17               |
| Minocha et al    | 33     | 4                         | 2                         | 15           | 7               | 12               |

Meta Analysis

| Study name         | Statistics for each study | Event rate and 95% CI |
|--------------------|---------------------------|-----------------------|
|                    | Event rate | Lower limit | Upper limit | Z-Value | p-Value |
| Chiotos et al      | 0.500      | 0.168       | 0.832       | 0.000   | 1.000   |
| Waltuch et al      | 0.100      | 0.006       | 0.674       | -1.474  | 0.140   |
| Wolff et al        | 0.917      | 0.378       | 0.995       | 1.623   | 0.105   |
| Grimaud et al      | 0.500      | 0.294       | 0.706       | 0.000   | 1.000   |
| Toubiana et al     | 0.381      | 0.203       | 0.598       | -1.080  | 0.280   |
| Whittaker et al    | 0.259      | 0.162       | 0.386       | -3.512  | 0.000   |
| Blondiaux et al    | 0.100      | 0.006       | 0.674       | -1.474  | 0.140   |
| Cheung et al       | 0.471      | 0.255       | 0.697       | -0.242  | 0.808   |
| Ramcharan et al    | 0.133      | 0.034       | 0.405       | -2.464  | 0.014   |
| Pouletty et al     | 0.688      | 0.433       | 0.864       | 1.462   | 0.144   |
| Kaushik et al      | 0.333      | 0.195       | 0.508       | -1.877  | 0.061   |
| Dufort et al       | 0.505      | 0.408       | 0.602       | 0.101   | 0.920   |
| Feldstein et al    | 0.392      | 0.325       | 0.464       | -2.910  | 0.004   |
| Riphagen et al     | 0.250      | 0.063       | 0.623       | -1.346  | 0.178   |
| Verdoni et al      | 0.200      | 0.050       | 0.541       | -1.754  | 0.080   |
| Belhadjer et al    | 0.400      | 0.253       | 0.567       | -1.175  | 0.240   |
| Matsubara et al    | 0.500      | 0.323       | 0.677       | 0.000   | 1.000   |
| Theocharis et al   | 0.100      | 0.025       | 0.324       | -2.948  | 0.003   |
| Gaitonde et al     | 0.333      | 0.131       | 0.624       | -1.132  | 0.258   |
| Valverde et al     | 0.336      | 0.283       | 0.392       | -5.452  | 0.000   |
| Minocha et al      | 0.333      | 0.195       | 0.508       | -1.877  | 0.061   |
|                   | 0.378      | 0.346       | 0.411       | -7.122  | 0.000   |

Fig. 3. The pooled prevalence of RT-PCR positivity for Covid-19 genome.
finally assessed different aspects of cardiovascular defects related to MIS-C among children suffering Covid-19. 2) The studies were restricted to English language, 3) the studies with unclear or irreproducible results were all excluded, 4) lack of access to the manuscripts full texts was also considered as the inclusion criteria unless the abstracts had enough data for our analysis, 5) case reports and review papers were all excluded. As shown in the flow diagram of the study selection [Fig. 1], 33 articles were initially collected by database searching. After removing 2 articles due to evidences of duplication, 31 records were primarily under-screened. Based on the titles and abstracts, 8 records were excluded and 23 citations were assessed for further eligibility. Based on the eligibility criteria; 3) searching the literature performed on a systematic and comprehensive approach; 4) to minimize the bias, inclusion and exclusion criteria predefined in the studies were comprehensively listed; 7) the publication and risk of bias were listed; and 8) heterogeneity was also assessed. The risk of bias for each study was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions and also according to QUADAS-2 tool. Any disagreement was resolved by discussion in the whole study team (see Table 2).

2.2. Data abstraction and validity assessment

Data abstraction was independently performed by two unblinded reviewers on structure collection forms without divergences in data collection. We resolved disagreements by consensus or by involving a third person. The study quality was evaluated based on the following criteria: 1) the systematic review and meta-analysis based on the questions primarily described and formulated; 2) inclusion and exclusion criteria predefined in the studies as eligibility criteria; 3) searching the literature performed on a systematic and comprehensive approach; 4) to minimize the bias, the full texts of the article were dually reviewed; 5) the quality of included studies were rated independently by the reviewers for appraising internal validity; 6) studies’ characteristics and findings were comprehensively listed; 7) the publication and risk of bias were assessed and presented by the pooled prevalence and 95% confidence interval (CI) as summary statistics. Cochran’s Q test was used to determine the statistical heterogeneity. This test was complemented with the I2 statistic, which quantifies the proportion of total variation across studies that is due to heterogeneity rather than chance. Publication bias was assessed by the rank correlation test and also confirmed by the funnel plot analysis. Reported values were two-tailed, and hypothesis testing results were considered statistically significant at $p = 0.05$. Statistical analysis was performed using the Comprehensive Meta Analysis (CMA) software version 3.0 (Biostat, Englewood, NJ 07631 USA).

3. Results

To assess the prevalence of cardiac abnormalities related to MIS-C based on applied keywords, in total 21 studies finally assessed that published from different countries between February

| Study name      | Event rate | Lower limit | Upper limit | Z-Value | p-Value | Event rate and 95% CI |
|-----------------|------------|-------------|-------------|---------|---------|-----------------------|
| Chiotoset al    | 0.667      | 0.268       | 0.916       | 0.800   | 0.423   |
| walltuch et al  | 0.900      | 0.326       | 0.994       | 1.474   | 0.140   |
| Wolff et al     | 0.600      | 0.200       | 0.900       | 0.444   | 0.657   |
| Grimaud et al   | 0.976      | 0.713       | 0.999       | 2.594   | 0.009   |
| Taubira et al   | 0.762      | 0.540       | 0.897       | 2.270   | 0.023   |
| Whitaker et al  | 0.310      | 0.205       | 0.440       | -2.813  | 0.005   |
| Blondiaux et al | 0.250      | 0.034       | 0.762       | -0.951  | 0.341   |
| Cheung et al    | 0.353      | 0.168       | 0.596       | -1.194  | 0.232   |
| Ramcharan et al | 0.800      | 0.530       | 0.934       | 2.148   | 0.032   |
| Pouletty et al  | 0.438      | 0.225       | 0.676       | -0.499  | 0.618   |
| Kaushik et al   | 0.121      | 0.046       | 0.282       | -3.714  | 0.000   |
| Dufort et al    | 0.515      | 0.417       | 0.612       | 0.301   | 0.763   |
| Feldstein et al | 0.484      | 0.413       | 0.556       | -0.440  | 0.660   |
| Riphagen et al  | 0.750      | 0.377       | 0.937       | 1.346   | 0.178   |
| Verdoni et al   | 0.500      | 0.225       | 0.775       | 0.000   | 1.000   |
| Belhadjer et al | 0.286      | 0.161       | 0.454       | -2.449  | 0.014   |
| Matsubar et al  | 0.393      | 0.233       | 0.580       | -1.125  | 0.261   |
| Theocharis et al| 0.400      | 0.214       | 0.620       | -0.868  | 0.374   |
| Gaitonde et al  | 0.667      | 0.376       | 0.869       | 1.132   | 0.258   |
| Valverde et al  | 0.206      | 0.163       | 0.257       | -9.221  | 0.000   |
| Minocha et al   | 0.121      | 0.046       | 0.282       | -3.714  | 0.000   |
|                | 0.380      | 0.346       | 0.415       | -6.581  | 0.000   |

**Fig. 4a.** The pooled prevalence of left ventricular dysfunction.
and October 2020 (Table 1). According to our risk of bias assessment, all 21 studies yielded good quality and none of the citation was determined to have high risk of bias and therefore the pooled results should be persuasive (Fig. 2). In total, 916 children were assessed indicating higher rate of boys than girls. The median age of the patients on admission was 9 years ranged 3 to 14 year.

Meta Analysis

| Study name                  | Event Rate | Lower Limit | Upper Limit | Z-Value | p-Value |
|-----------------------------|------------|-------------|-------------|---------|---------|
| Chiotosetal                 | 0.167      | 0.023       | 0.631       | -1.469  | 0.142   |
| Waltuchetal                 | 0.750      | 0.238       | 0.966       | 0.951   | 0.341   |
| Toubianaetal                | 0.238      | 0.103       | 0.460       | -2.270  | 0.023   |
| Whittakeretal               | 0.138      | 0.071       | 0.252       | -4.813  | 0.000   |
| Cheungetal                  | 0.412      | 0.210       | 0.648       | -0.724  | 0.469   |
| Ramcharanetel               | 0.933      | 0.648       | 0.991       | 2.550   | 0.011   |
| Pouleptyetal                | 0.188      | 0.062       | 0.447       | -2.289  | 0.022   |
| Kaushiketel                 | 0.182      | 0.084       | 0.350       | -3.333  | 0.001   |
| Dufortetal                  | 0.091      | 0.048       | 0.166       | -6.586  | 0.000   |
| Feldsteinet al              | 0.081      | 0.049       | 0.129       | -9.037  | 0.000   |
| Riphagenetel                | 0.125      | 0.017       | 0.537       | -1.820  | 0.069   |
| Verdonietal                 | 0.200      | 0.050       | 0.541       | -1.754  | 0.080   |
| Matsubaraetal               | 0.143      | 0.055       | 0.324       | -3.318  | 0.001   |
| Theocharisetal              | 0.150      | 0.049       | 0.376       | -2.770  | 0.006   |
| Valverdeental               | 0.286      | 0.218       | 0.320       | -7.593  | 0.000   |
| Minochaetal                 | 0.061      | 0.015       | 0.212       | -3.757  | 0.000   |
|                             | 0.200      | 0.172       | 0.231       | -14.717 | 0.000   |

Meta Analysis

Fig. 4b. The pooled prevalence of coronary artery aneurism/dilatation.

Meta Analysis

| Study name                  | Event Rate | Lower Limit | Upper Limit | Z-Value | p-Value |
|-----------------------------|------------|-------------|-------------|---------|---------|
| Wolffer al                  | 0.200      | 0.027       | 0.691       | -1.240  | 0.215   |
| Toubiana et al              | 0.095      | 0.024       | 0.311       | -3.028  | 0.002   |
| Whittaker et al             | 0.103      | 0.047       | 0.212       | -5.009  | 0.000   |
| Blondiaux et al             | 0.500      | 0.123       | 0.877       | 0.000   | 1.000   |
| Cheung et al                | 0.235      | 0.091       | 0.486       | -2.061  | 0.039   |
| Ramcharan et al             | 0.600      | 0.348       | 0.808       | 0.769   | 0.442   |
| Feldstein et al             | 0.065      | 0.037       | 0.110       | -8.960  | 0.000   |
| Riphagen et al              | 0.125      | 0.017       | 0.537       | -1.820  | 0.069   |
| Belhadjer et al             | 0.057      | 0.014       | 0.202       | -3.850  | 0.000   |
| Valverde et al              | 0.353      | 0.300       | 0.410       | -4.892  | 0.000   |
| Minocha et al               | 0.455      | 0.296       | 0.623       | -0.522  | 0.602   |
|                             | 0.281      | 0.244       | 0.321       | -9.549  | 0.000   |

Meta Analysis

Fig. 4c. The pooled prevalence of ECG abnormalities.
### Study name Statistics for each study

| Event name     | Event rate | Lower limit | Upper limit | Z-Value p-Value |
|---------------|------------|-------------|-------------|-----------------|
| Chiotos et al | 0.500      | 0.168       | 0.832       | 0.000 1.000     |
| Waltuch et al | 0.750      | 0.238       | 0.966       | 0.951 0.341     |
| Toubiana et al| 0.810      | 0.588       | 0.927       | 2.604 0.009     |
| Blondiaux et al| 0.900 | 0.326      | 0.994       | 1.474 0.140     |
| Cheung et al  | 0.824      | 0.573       | 0.942       | 2.421 0.015     |
| Ramcharan et al| 0.969 | 0.650      | 0.998       | 2.390 0.017     |
| Pouletty et al| 0.688      | 0.433       | 0.864       | 1.462 0.144     |
| Dufort et al  | 0.636      | 0.537       | 0.725       | 2.679 0.007     |
| Feldstein et al| 0.269 | 0.210      | 0.337       | -6.050 0.000    |
| Riphagen et al| 0.125      | 0.017       | 0.537       | -1.820 0.069    |
| Verdoni et al | 0.500      | 0.225       | 0.775       | 0.000 1.000     |
| Belhadjer et al| 0.029 | 0.004      | 0.177       | -3.476 0.001    |
| Valverde et al| 0.070      | 0.046       | 0.106       | -11.161 0.000   |
| Minocha et al | 0.212      | 0.105       | 0.383       | -3.082 0.002    |
| 0.333         | 0.291      | 0.378       | -6.949      | 0.000           |

**Fig. 4d.** The pooled prevalence of raised serum troponin level.

### Study name Statistics for each study

| Event name     | Event rate | Lower limit | Upper limit | Z-Value p-Value |
|---------------|------------|-------------|-------------|-----------------|
| Chiotos et al | 0.500      | 0.168       | 0.832       | 0.000 1.000     |
| Waltuch et al | 0.750      | 0.238       | 0.966       | 0.951 0.341     |
| Toubiana et al| 0.810      | 0.588       | 0.927       | 2.604 0.009     |
| Blondiaux et al| 0.900 | 0.326      | 0.994       | 1.474 0.140     |
| Cheung et al  | 0.824      | 0.573       | 0.942       | 2.421 0.015     |
| Ramcharan et al| 0.969 | 0.650      | 0.998       | 2.390 0.017     |
| Pouletty et al| 0.688      | 0.433       | 0.864       | 1.462 0.144     |
| Dufort et al  | 0.636      | 0.537       | 0.725       | 2.679 0.007     |
| Feldstein et al| 0.269 | 0.210      | 0.337       | -6.050 0.000    |
| Riphagen et al| 0.125      | 0.017       | 0.537       | -1.820 0.069    |
| Verdoni et al | 0.500      | 0.225       | 0.775       | 0.000 1.000     |
| Belhadjer et al| 0.029 | 0.004      | 0.177       | -3.476 0.001    |
| Valverde et al| 0.070      | 0.046       | 0.106       | -11.161 0.000   |
| Minocha et al | 0.212      | 0.105       | 0.383       | -3.082 0.002    |
| 0.333         | 0.291      | 0.378       | -6.949      | 0.000           |

**Fig. 4e.** The pooled prevalence of raised serum NT-ProBNP level.
Contrary to the impression, the molecular assessment of virus using the RT-PCR (Fig 3) led to wide positive test results with the pooled positivity of 37.7% (95%CI: 32.2% to 43.7%). Considering studies focusing different cardiac abnormalities related to MIS-C yielded a pooled prevalence of 38.0% (95%CI: 34.6% to 41.5%) for significant left ventricular dysfunction, 20.0% (95%CI: 17.2% to 23.1%) for coronary aneurism or dilatation, 28.1% (95%CI: 24.4% to 32.1%) for EG abnormalities or cardiac arrhythmias, 33.3% (95%CI: 29.1% to 37.8%) for raised serum troponin level and 43.6% (95%CI: 39.2% to 48.1%) for raised proBNP/BNP level (Figs. 4a–e). The statistical heterogeneity was significant for all events assessment with I² values ranged 75.456 to 97.249 (P < 0.001). The authors believed that the pointed heterogeneities were sourced from the differences in the interpretation of the ECG or echocardiography by specialists and also the lack of calibration of the instruments used. There was also a significant publication bias as evidenced by either funnel plot asymmetry or Egger test for all assessments due to the publishers’ desire to publish articles with significant and positive results. The main echocardiography findings in the studies evaluated were hypokinesia of the left ventricle wall and interventricular septum, left ventricular dilatation, mild to moderate pericardial effusion, mild mitral regurgitation, cardiogenic shock, myocarditis, or coronary artery dilatation/aneurism/ectasia. Regarding ECG abnormalities, the prominent findings included ST-segment elevation or depression, junctional cardiac rhythm, atrial fibrillation, sinus bradycardia, QT interval prolongation, ventricular arrhythmias, and atrioventricular block.

4. Discussion

According to the findings of the present systematic review and meta-analysis, various dimensional and functional changes are expected following MIS-C due to Covid-19 in children. In this regard, both left ventricular myocardial tissue as well as coronary arteries can be affected significantly by such critical situation so that overall more than one-third of the patients may show a degree of such abnormal cardiac conditions. As analyzed finally, about 38.0% of the pointed children suffered from significant (mild to moderate) left ventricular dysfunction which accompanied with diffuse left ventricular hypokinesia along with dilatation, 20.0% from coronary arteries involvement as aneurism, dilatation or ectasia, and 28.1% from different types of ECG abnormalities as atrial or ventricular arrhythmias. Interestingly, such cardiac changes could be accompanied with the raise of both cardiac enzyme (troponin) and also cardiac function-related proteins (NT-proBNP) in 33.3% and 43.6% respectively. The evidences have been shown that mild cardiac changes in those children suffering Covid-19 [7,8], however if accompanied by MIS-C, a notable number of children affected by Covid-19 may suffered from serious cardiac complications may lead to high mortality rates. Of course, it is not yet clear whether the occurrence of such complications is related to the severity and extent of Covid-19 disease. As shown in this study, a significant proportion of patients had a negative result of tracing the genome of the virus and in fact the diagnosis was based mainly on clinical manifestations, but it has been also shown that majority of affected children had high titters of antibodies as well as elevated inflammatory biomarkers and trigger cytokines explaining a close link between the severity of Covid-19 and cardiac complications even among children. As a general guideline, children suffering MIS-C need to intensive cares due to multi-organ dysfunction and thus such caring approaches should be more emphasized in case of appearing any evidences of cardiac involvement. In this regard, continuous hemodynamic and cardiac monitoring, using cardiac inotropes, preserving arterial oxygen saturation, using intravenous immunoglobulin (IVIG) and immunomodulators should be considered in such patients [34,35].

References

[1] WHO Coronavirus Disease (COVID-19) Dashboard. The World Health Organization, Data last updated: 2020/12/9. Available in: [https://covid19.who.int/]

[2] Francesca Mai, Rita Del Pinto, Claudio Ferri, COVID-19 and cardiovascular disorders. J. Cardiol. 76 (2020) 452–458.

[3] Bansal M. Cardiovascular disease and COVID-19.Diabetes Metab Syndr. 2020 May-Jun;14(3):247–250. doi: 10.1016/j.dsx.2020.03.013. Epub 2020 Mar 25.

[4] KJ. Clerkin, J.A. Fried, J. Raikhelkar, C. Sayer, A. Masoumi, S.S. Jain, D. Burkhoff, D. Kumariah, L. Rabban, A. Schachar, J. Gury, COVID-19 and Cardiovascular Disease. Circulation 141 (2020) 2020 May 19; 1648–1655. [https://doi.org/10.1161/CIRCULATIONAHA.120.049641]. Epub 2020 Mar 21.

[5] A. Akhmerov, E. Marban, COVID-19 and the Heart, Circ Res. 126 (10) (2020) 8–1443–1455. [https://doi.org/10.1161/CIRCRESAHA.120.057055]. Epub 2020 Apr 7.

[6] C. Chen, C. Chen, J.T. Yan, N. Zhou, J.P. Zhao, Wang, Analysis of myocardial injury in patients with COVID-19 and association between comitant cardiovascular diseases and severity of COVID-19, Zhonghua Xin Xue Guan Bing Za Zhi. 48 (7) (2020 Jul 24) 567–571. [https://doi.org/10.3760/cma.j.cn112148-20200225-00123].

[7] J.F. Ludwigsson, Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults, Acta Paediatr. 109 (2020) 1088–1095.

[8] Giulia Sanna, Gaia Serrau, Pier Paolo Bassareo, Paola Neroni, Vassilios Fanos, Maria Antonietta Marcialis. Children’s heart and COVID-19: Up-to-date evidence in the form of a systematic review. Eur J Pediatr. 2020 Mar; 1: 39–.

[9] Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; e20200702.

[10] Mubbasher Ahmed, Shailesh Advani,b,1 Axel Moreira,a Sarah Zoretic,d John Martinez,d Kevin Chorath, Sebastian Acosta,a Rija Naqvi,b,1,De Finn Burmeister-Morton,d Fiona Burmeister,d Ana Tarresiel,d Matthew Petersbach, d Mary Evans,d, Ansel Hoang,d, Karthik Rajasekaran,e Sunil Ahuja,d and Alvaro Moreira. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020 Sep; 26: 100527.

[11] Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. Published May 14, 2020. [https://emergency.cdc.gov/han/2020/han00432.asp] (accessed August 5, 2020).

[12] A.H. Rowley, Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children, Nat Rev Immunol. 20 (8) (2020 Aug) 453–454. [https://doi.org/10.1038/s41577-020-0367-5].

[13] Belhadjer Z, Mënôt M, Bajolle F et al., 2020. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 33. [https://doi.org/10.1161/CIRCULATIONAHA.120.048360].

[14] E. Blondiaux, P. Parison, A. Redheuil, et al., Cardiac MRI of children with multisystem Inflammatory Syndrome (MIS-C) associated with COVID-19: case series Éléonore, Radiology 78 (2012) 1–15.

[15] E.W. Cheung, P. Zachariah, M. Gorelik, et al., Multisystem inflammatory syndrome in children related to COVID-19 in previously healthy children and adolescents in New York city, Jama J. Am. Med. Assoc. 8–10 (2020). [https://doi.org/10.1001/jama.2020.10374].

[16] K. Chiotis, H. Bassiri, E.M. Behrens, et al., Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J. Pediatric. Infect. Dis. Soc. (2020). [https://doi.org/10.1016/j.pais.2020.06.009].

[17] E.M. Dufort, E.H. Koumans, E.J. Chow, et al., Multisystem inflammatory syndrome in children, Nat Engl. J. Med. 1–2 (2020). [https://doi.org/10.1056/NEJMoa2001756].

[18] L.R. Feldstein, E.B. Rose, S.M. Horwitz, et al., Multisystem inflammatory syndrome in U.S. children and adolescents, N Engl J Med (2020) 1–13, [https://doi.org/10.1056/NEJMoa201680].

[19] Mansi Gaitonde 1, Daniel Ziebel 1, Michael S Kelleman 2, David E Cox 3, Joan Lipidon 1, William 1, Forster 1, Ritu Sachdeva 1, COVID-19 Related Multisystem Inflammatory Syndrome in Children Affects Left Ventricle Function and Global Strain Compared with Kawasaki Disease. J Am Soc Echocardiogr. 2020 Oct;33(10):1285-1287. doi: 10.1016/j.echo.2020.07.019. Epub 2020 Jul 31.

[20] M. Grimaud, J. Stark, M. Levy, et al., Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children, Ann Intensive Care 10 (2020) 1–5, [https://doi.org/10.1016/j.jpeds.2020.06.045].

[21] S. Kaushik, S.I. Aydin, K.R. Derespina, et al., Multisystem inflammatory syndrome in children (MIS C) associated with SARS-CoV-2 infection: a multi-institutional study from New York City, J. Pediatr. 2–7 (2020),https://doi.org/10.1016/j.jpeds.2020.06.045.
Cardiac Findings in Pediatric Patients With Multisystem Inflammatory Syndrome in Children Associated With COVID-19. Clin Pediatr (Phila). 2020 Sep 25;9922820961771. doi: 10.1177/0009922820961771.

M. Pouletty, C. Borocco, N. Ouldali, et al., Paediatric multisystem inflammatory syndrome temporally associated with SARSCoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 999–1006 (2020), https://doi.org/10.1136/annrheumdis-2020-217965.

T. Ramcharan, O. Nolan, C.Y. Lai, et al., Paediatric inflammatory multisystem syndrome temporally associated with SARSCoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr. Cardiol. (2020). 2.https://doi.org/10.1007/s00046-020-02391-2.

S. Riphagen, X. Gomez, C. Gonzalez-martinez, et al., Hyperinflammatory shock in children during COVID-19 pandemic, Lancet 395 (2020) 1607–1608, https://doi.org/10.1016/S0140-6736(20)31094-1.

Paraskevi Theocharis 1, James Wong 1, Kuberan Pushparajah 1 2, Sujeev K Mathur 1, John M Simpson 1, Emma Pascall 1, Aoise Cleary 1, Kirsty Stewart 1, Kastav Adhvaryu 1, Alex Savis 1, Saleha R Kabir 1, Mirasol Pernia Uy 1, Hannah Heard 1, Kelly Peacock 1, Owen Miller 1 3. Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19. Eur Heart J Cardiovasc Imaging. 2020 Aug 7;eea212. doi: 10.1093/ehjci/eea212. Online ahead of print.

J. Houhiana, C. Poirault, A. Corsa, et al., Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study, Br. Med. J. 1–7 (2020). https://doi.org/10.1136/bmj.m2694.

Israel Valverde 1, Yogen Singh 2, Joan Sanchez-de-Toledo 3, Paraskevi Theocharis 4, Ashish Chikermane 5, Sylvie Di Filippo 6, Beata Kucinska 7, Savina Mannarino 8, Amalia Tamariz-Martel 9, Federico Gutierrez-Larraya 10, Giridhar Soda 11. Acute Cardiovascular Manifestations in 286 Children with Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in Europe. Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050065.

L. Verdoni, A. Mazza, A. Gervasoni, et al., An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARSCoV-2 epidemic: an observational cohort study. Lancet 6736 (2020) 1–8, https://doi.org/10.1016/S0140-6736 (20)31103-X.

T. Waltuch, P. Gill, I.E. Zinzis, R. Whitney, J. Tokarski, J.W. Tsung, J.E. Sanders, Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department, Am. J. Emerg. Med. (2020), https://doi.org/10.1016/j.ajem.2020.05.058.

E. Whittaker, A. Bamford, J. Kenny, et al., Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA –, J. Am. Med. Assoc. (2020) 1–11, https://doi.org/10.1001/jama.2020.10369.

A. Wolffl, S. Mannarino, V. Ghielmetti, et al., Acute myocardial injury: a novel clinical pattern in children with COVID-19. Lancet Child Adolesc. Heal. 4642 (2020) 1016–1017, https://doi.org/10.1016/S2352-4642(20)30168-1.

American College of Rheumatology. Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARSCoV-2 and Hyperinflammation in COVID-19. Availablefrom: https://www.rheumatology.org/ Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-MIS-CHyperinflammation.pdf. Accessed August 7, 2020.

A. Hassoun, E.D. Thottacherry, J. Muklewicz, Q.U. Aziz, J. Edwards, Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19, J. Clin. Virol. 128 (2020) 104443.